Epithelial–mesenchymal transition (EMT) is a biological process that involves the transformation of epithelial cells into ...

Diabetic neuropathy is a common, progressive complication of diabetes characterized by nerve damage that leads to chronic ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the co ...

References: 1.  Thailand Food and Drug Administration. Public Pharmaceutical Regulatory Information: NERLYNX. Available at: ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ ...

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...

Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHME ...